The effect of synbiotics therapy on microbiome of obesity

The effect of synbiotics therapy on microbiome of obesity - Can synbiotics therapy effectively affect microbiome? (STEAM)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025800

Enrollment

Registered

2017-01-24

Start date

2017-01-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity and obesity related diseases

Interventions

12 weeks administration of Bifidobacterium breve B-3, galacto- and fructo- oligosaccharide, and indigestible dextrin. 12 weeks administration of maltodextrin, glucose liquid sugar, dextrin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: BMI25.0-34.9 Outpatients No significant changes of body weight for 3 months

Exclusion criteria

Exclusion criteria: A patient who has 1. type 2 diabetes, dyslipidemia, or hypertension which starts or changes medication for treatment during last 6 months 2. > 1% Changes of HbA1c during last 3 months 3. history of severe food allergies 4. history of Inflammatory bowel diseases or cancer in the digestive system 5. history of surgery for the digestive system 6. Antibiotics therapy for last 3 months 7. severe psychiatric illness

Design outcomes

Primary

Measure	Time frame
BMI 12 weeks after synbiotics administration	—

Secondary

Measure	Time frame
BMI 24 weeks after treatment, fasting blood glucose, lipid, Obesity related diseases, microbiome, adipocytokine, bile acid	—

Countries

Japan

Contacts

Public ContactItoe Yamamoto

Tokyo Metropolitan Tama Medical Center Department of Surgery

shimizh@outlook.com0423235111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026